TP53 and breast cancer: In the BC clinical context analyzed in this study, our results confirmed that the mutational status of ctDNA always resembles the tissue characteristics and pointed out that circulating biomarkers reveal additional information (e.g., novel TP53 and ESR1 alterations in Pt#61 and Pt#60).